Comparison of Characteristics Between ICS-Treated COPD Patients and ICS-Treated COPD Patients with Concomitant Asthma: A Study in Primary Care

References

• Global strategy for the diagnosis, management and prevention of COPD, global initiative for chronic obstructive lung disease (GOLD); 2018 Available from: http://goldcopd.org/gold-reports/.
   Google Scholar
• YangIA, ClarkeMS, SimEH, FongKM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:Cd002991.
   PubMed Web of Science ®Google Scholar
• CalverleyPM, AndersonJA, CelliB, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• NanniniLJ, LassersonTJ, PooleP. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:Cd006829.
   PubMed Web of Science ®Google Scholar
• NanniniLJ, PooleP, MilanSJ, KestertonA. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;8:Cd006826.
   PubMed Web of Science ®Google Scholar
• BourbeauJ, SebaldtRJ, DayA, et al. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J. 2008;15(1):13–19. doi:10.1155/2008/17390418292848
   PubMed Web of Science ®Google Scholar
• FitchK, IwasakiK, PyensonB, et al. Variation in adherence with global initiative for chronic obstructive lung disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin. 2011;27(7):1425–1429. doi:10.1185/03007995.2011.58323021599554
   PubMed Web of Science ®Google Scholar
• LucasAE, SmeenkF, SmeeleI, et al. Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. Fam Pract. 2008;25(2):86–91. doi:10.1093/fampra/cmn00618304973
   PubMed Web of Science ®Google Scholar
• DahlR, ChungKF, BuhlR, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473–479. doi:10.1136/thx.2009.12543520522841
   PubMed Web of Science ®Google Scholar
• JonesPW, MahlerDA, GaleR, et al. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med. 2011;105(6):892–899. doi:10.1016/j.rmed.2011.02.01321397482
   PubMed Web of Science ®Google Scholar
• WedzichaJA, CalverleyPMA, SeemungalTA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26. doi:10.1164/rccm.200707-973OC17916806
   PubMed Web of Science ®Google Scholar
• JansonC, LarssonK, LisspersKH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306. doi:10.1136/bmj.f330623719639
   PubMed Web of Science ®Google Scholar
• GonzalezAV, CoulombeJ, ErnstP, et al. Long-term use of inhaled corticosteroids in COPD and the risk of fracture. Chest. 2018;153(2):321–328. doi:10.1016/j.chest.2017.07.00228716642
   PubMed Web of Science ®Google Scholar
• PriceDB, RussellR, MaresR, et al. Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study. PLoS One. 2016;11(9):e0162903. doi:10.1371/journal.pone.016290327658209
   PubMed Web of Science ®Google Scholar
• ChalmersJD, TebbothA, GayleA, et al. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. NPJ Prim Care Respir Med. 2017;27(1):43. doi:10.1038/s41533-017-0040-z28663549
   PubMed Web of Science ®Google Scholar
• VestboJ, VogelmeierC, SmallM, et al. Understanding the GOLD 2011 Strategy as applied to a real-world COPD population. Respir Med. 2014;108(5):729–736. doi:10.1016/j.rmed.2014.03.00224675239
   PubMed Web of Science ®Google Scholar
• SuissaS, BarnesPJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J. 2009;34(1):13–16. doi:10.1183/09031936.0019090819567599
   PubMed Web of Science ®Google Scholar
• BatemanED, ReddelHK, van Zyl-smitRN, et al. The asthma-COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3(9):719–728. doi:10.1016/S2213-2600(15)00254-426255108
   PubMed Web of Science ®Google Scholar
• PostmaDS, RabeKF. The asthma-COPD overlap syndrome. N Engl J Med. 2015;373(13):1241–1249. doi:10.1056/NEJMra141186326398072
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2019 Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.6-FINAL-08Nov2018-wms.pdf.
   Google Scholar
• SavranO, GodtfredsenN, SørensenT, et al. COPD patients prescribed inhaled corticosteroid in general practice: based on disease characteristics according to guidelines? Chron Respir Dis. 2019;16:1479973119867949. doi:10.1177/147997311986794931431060
   PubMed Web of Science ®Google Scholar
• BestallJC, PaulEA, GarrodR, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581–586. doi:10.1136/thx.54.7.58110377201
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2017 Available from: http://goldcopd.org.
   Google Scholar
• TamimiA, SerdarevicD, HananiaNA. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med. 2012;106(3):319–328. doi:10.1016/j.rmed.2011.11.00322196881
   PubMed Web of Science ®Google Scholar
• BafadhelM, PetersonS, De BlasMA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. doi:10.1016/S2213-2600(18)30006-729331313
   PubMed Web of Science ®Google Scholar
• DyerCA, SinclairAJ. A hospital-based case-control study of quality of life in older asthmatics. Eur Respir J. 1997;10(2):337–341. doi:10.1183/09031936.97.100203379042629
   PubMed Web of Science ®Google Scholar
• SeigelWM, GoldenNH, GoughJW, et al. Depression, self-esteem, and life events in adolescents with chronic diseases. J Adolesc Health Care. 1990;11(6):501–504. doi:10.1016/0197-0070(90)90110-N2262397
   PubMedGoogle Scholar
• WoledesenbetMA, Shumet MekonenS, SoriLM, et al. Epidemiology of depression and associated factors among asthma patients in Addis Ababa, Ethiopia. Psychiatry J. 2018;2018:5934872. doi:10.1155/2018/593487230225243
   PubMedGoogle Scholar
• YehJJ, LinC-L, HsuW-H, et al. The relationship of depression in asthma-chronic obstructive pulmonary disease overlap syndrome. PLoS One. 2017;12(12):e0188017. doi:10.1371/journal.pone.018801729232717
   PubMed Web of Science ®Google Scholar